Old and new acetylcholinesterase inhibitors for Alzheimer’s disease
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: To date, pharmacological treatment of Alzheimer's disease (AD) includes Acetylcholinesterase Inhibitors (AChEIs) for mild-to-moderate AD, and memantine for moderate-to-severe AD. AChEIs reversibly inhibit acetylcholinesterase (AChE), thus increasing the availability of acetylcholine in cholinergic synapses, enhancing cholinergic transmission. These drugs provide symptomatic short-term benefits, without clearly counteracting the progression of the disease. AREAS COVERED: On the wake of successful clinical trials which lead to the marketing of AChEIs donepezil, rivastigmine and galantamine, many compounds with AChEI properties have been developed and tested mainly in Phase I-II clinical trials in the last twenty years. Here, we review clinical trials initiated and interrupted, and those ongoing so far. EXPERT OPINION: Despite many clinical trials with novel AChEIs have been carried out after the registration of those currently used to treat mild to moderate AD, none so far has been successful in a Phase III trial and marketed. Alzheimer's disease is a complex multifactorial disorder, therefore therapy should likely address not only the cholinergic system but also additional neurotransmitters. Moreover, such treatments should be started in very mild phases of the disease, and preventive strategies addressed in elderly people.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Traditional AD drugs (Fig. 5) are categorized into two classes: AChEIs (tacrine (3), donepezil (4), rivastigmine (5), galantamine (6)) and NMDA receptor antagonists (memantine (7)).396”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [396]
Citations
Cites
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · cited 1×
“Dimebon was safe, well tolerated, and showed significant benefits in ADAS-cog [9].”
BackgroundMedhurst, A. D., Atkins, A. R., Beresford, I. J., Brackenborough, K., Briggs, M. A., Calver, A. R., Cilia, J., Cluderay, J. E., Crook, B., Davis, J. B., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120311 · Cited by 301 · cited 1×
“In mice and rats, inhibiting this receptor has been shown to enhance cholinergic signaling, reduce tau phosphorylation, and reverse behavioral deficits [22,23].”
BackgroundYang, G., Wang, Y., Tian, J., & Liu, J.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074916 · Cited by 241 · cited 2×
“their findings cautiously, due to the poor methodological quality of the trials included [7].”
BackgroundWeinreb, O., Amit, T., Bar-Am, O., & B.H. Youdim, M. (2012) · Current Drug Targets · doi:10.2174/138945012799499794 · Cited by 153 · cited 1×
“Finally, it possesses potent antiapoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models (see [39] for review).”
BackgroundLin, C., Chen, P.-K., Chang, Y., Chuo, L.-J., Chen, Y.-S., Tsai, G. E., & Lane, H. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.010 · Cited by 143 · cited 1×
“D-amino acid oxidase inhibitor, gave promising results [55].”
BackgroundGrove, R., Harrington, C., Mahler, A., Beresford, I., Maruff, P., Lowy, M., Nicholls, A., Boardley, R., Berges, A., Nathan, P., et al. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131212110148 · Cited by 109
Huperzine A for Alzheimer's disease
Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., & Dong, B. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005592.pub2 · Cited by 108
Lemes, L. F. N., Ramos, G. D. A., de Oliveira, A. S., da Silva, F. M. R., Couto, G. C., Boni, M. S., Guimarães, M. J. R., Souza, I. N. D. O., Bartolini, M., Andrisano, V., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.12.024 · Cited by 100 · cited 1×
“A number of novel compounds have been synthesized and studied from a pharmacological and biochemical point of view or in mouse and rat models, including novel tacrine-related cholinesterase inhibitors [45], novel 7-aminoalkyl-substituted flavonoid derivatives [46], racemic benzochromenopyrimidinimines [47], Schiff bas…”
BackgroundA Randomized Study of H3 Antagonist ABT-288 in Mild-To-Moderate Alzheimer's Dementia1
Haig, G. M., Pritchett, Y., Meier, A., Othman, A. A., Hall, C., Gault, L. M., & Lenz, R. A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140291 · Cited by 71 · cited 1×
“cally inferior to placebo but no statistical differences were detected [25].”
BackgroundNathan, P. J., Boardley, R., Scott, N. E., Berges, A., Maruff, P. T., Sivananthan, T., Upton, N., Lowy, M. T., Nestor, P. J., & Lai, R. Y. K. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310030003 · Cited by 69 · cited 1×
“and had positive effects on tasks of attention and memory[17].”
Background
Research works printed but not linked: 2
- Birks J, 2006, Cochrane Database Syst Rev, 1, CD005593
- Abd Razik BM, 2016, Med Chem, 12
Cited by
Items 101–126 of 126
Lee, S. E., Park, S.-B., Kweon, H., Park, J.-Y., Lee, J., Jo, Y., Lee, J., Jang, G. Y., Choi, S.-J., & Kim, D. (2021) · Korean Journal of Food Preservation · doi:10.11002/kjfp.2021.28.7.989 · Cited by 1
Tavares, J., Oliveira, A. V., Nascimento, T. D. S., Soares, M. S. P., de Paiva, J. R., Braz, H. L. B., Jorge, R. J. B., Canuto, K. M., Gomes, J. M. P., Benjamin, S. R., et al. (2024) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-024-00595-8 · Cited by 1
“Galantamine is a reversible and competitive inhibitor of AChE (Galimberti and Scarpini 2016) and enhances the intrinsic action of ACh on nicotinic receptors, which have been shown to be reduced in AD, and act synergistically with ACh to increase nAChRs activation (Samochocki et al. 2003).”
Charles Bonnet Syndrome in an Elderly Patient Following Cataract Surgery
Akinyemi, A., Dabul, L., Cabrera, E., Akinyemi, L., Oms, J. D., & Benito, J. (2017) · Journal of psychiatry · doi:10.4172/2378-5756.1000414
Neurological Disorders and Challenging Intervention in Xeroderma Pigmentosum and Cockayne Syndrome
Hayashi, M. (2018) · Springer eBooks · doi:10.1007/978-981-10-6722-8_7 · Cited by 1
Investigations of new methods for studying molecular dynamics with elastic neutron scattering
Zeller, D. (2019) · theses.fr (ABES) · doi:10.70675/3648c638ze142z4806zbc6eze005181e13d5
Ndongo, T. M., Passos, M. L. C., Durães, F., Resende, D. I. S. P., Pinto, M. M. M., Sousa, E., & Saraiva, M. L. M. F. S. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100150
Mahmoodi, G., & Moshfegh, A. (2021) · journal of ilam university of medical sciences · doi:10.52547/sjimu.29.3.92
Prado, K. E. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2022.tde-25082022-094948
NATURAL PRODUCT-BASED AMYLOID PROTEIN INHIBITORS
Swagath, S., & Suseem, S. R. (2022) · Innovare Journal of Sciences · doi:10.22159/ijs.2022.v10i1.41079
In Silico Design of Acetylcholinesterase and Glycogen Synthase Kinase-3β Multi-target Inhibitors
Picanço, L. C. D. S., Silva, G. M., de Oliveira, N. K. S., de Souza, L. R., Pontes, F. M. M., Francischini, I. A. G., da Silva, C. H. T. D. P., Taft, C. A., de Molfetta, F. A., & Hage-Melim, L. I. D. S. (2023) · Engineering materials · doi:10.1007/978-3-031-46545-1_20
Srinivasan, T. B., Chandrapragasam, V., & Jacob, A. (2025) · Journal of Applied and Natural Science · doi:10.31018/jans.v17i3.6647
“moderate stages of Alzheimer's disease (AD) (Galimberti and Scarpini, 2016).”
Jia, X., Li, M., Wang, Y., Li, H., Zhang, X., Chen, H., Tian, J., Zhang, G., & Wang, T. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115965
Phosphonates and the brain, from diagnostics to medicines for neurological disorders
Braga, S. S., Santos, N. E., Almeida-Santos, M., Figueira, F., & Paz, F. A. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33374-3.00016-5 · Cited by 1
Využití indoxylacetátu jako chromogenního a fluorogenního substrátu pro cholinesterasy
Škvorová, K. (2023) · Digital library - University of Pardubice (University of Pardubice)
Shao, D., Liang, S., Xiong, Y., & Liang, G. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag153
“To counteract this process, acetylcholinesterase inhibitor (AChEIs) specifically block AChE activity, slowing ACh degradation, enhancing synaptic ACh availability, and ultimately improving cognitive function (Galimberti and Scarpini 2016).”
Recent Advances in Drug Development for the Management of Alzheimer’s Disease
Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Unlocking the Potential of Isatin Scaffolds in Acetylcholinesterase Inhibition
Tharwat, T., El‐Nassan, H. B., Adly, M. E., & Kamel, M. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70336
Fitriana, L. A., Ufamy, N., Mahmudah, R., Rahmi, U., Rohaedi, S., & Adnyana, I. K. (2026) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.22.s9.40
Hadi, S. (2026) · Digital Library UIN Sunan Kalijaga (Sunan Kalijaga State Islamic University)
Lee, S., Kim, K., Kim, H., Oh, M.-S., Yoon, K., Kwak, S., Kim, J., Lee, G., Kim, Y., & Kim, J. (2026) · Experimental Neurobiology · doi:10.5607/en26028
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Galimberti, D., & Scarpini, E.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Galimberti, Daniela
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2016-08-05
- Volume
- 25
- Issue
- 10
- Pages
- 1181-1187
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2487848811
- Cited by
- 117
- References
- 27
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 7 · 2023: 11 · 2022: 8 · 2021: 18 · 2020: 14 · 2019: 11 · 2018: 11 · 2017: 14 · 2016: 1
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Investigational Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- acetylcholinesterase inhibitors, Alzheimer's disease, donepezil, rivastigmine, galantamine, memantine, cholinergic neurotransmission, acetylcholine, clinical trials, drug development, early treatment, multifactorial therapy
- MeSH terms
- Acetylcholine, Aged, Alzheimer Disease, Animals, Cholinesterase Inhibitors, Humans, Severity of Illness Index, Drug Design, Treatment Outcome, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.